Cardiovascular Advances in Research and Opportunities Legacy Act became law 666 days after introduction, with cosponsors from both parties
Written by the Congressional Research Service [2]. 125 words.
Cardiovascular Advances in Research and Opportunities Legacy Act This act addresses research, education, and awareness concerning valvular heart disease and its treatment. This disease is caused by damage to or disease affecting any valve that controls blood flow in the heart. The National Institutes of Health may conduct or support research on the disease in consultation with the National Heart, Lung, and Blood Institute (NHLBI). The NHLBI must also conduct a workshop on mitral valve prolapse, which occurs when the valve between the chambers of the left side of the heart seals improperly. The Department of Health and Human Services (HHS) must develop best practices to treat valvular heart disease. HHS may also carry out other projects to increase education and awareness of the disease.
- Committees
- House Energy and Commerce Committee
Senate Health, Education, Labor, and Pensions Committee - Policy area
- Health: 122 of 9,357 bills became law, 113th–118th (1.3%)
- Sponsor
- 4 of 203 bills enacted since 2013
- Text versions
- 9, from enrolled bill to public law · 892 words
- Subjects
- Advanced technology and technological innovationsCardiovascular and respiratory healthGovernment information and archivesHealth information and medical recordsHealth programs administration and fundingHealth promotion and preventive care +5 more
- Latest action
- Dec 20, 2022: Became Public Law No: 117-244.
- Records
- Congress.gov · Bill text
Each bill appears once, under its strongest link. 1 in all.
Related, per CRS or House · 1
- 117th S. 1133 Cardiovascular Advances in Research and Opportunities Legacy Act R · Introduced